Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 9,976 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TARGET Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Intercostobrachial Nerve Block's Effect on Pain Control After Shoulder Replacement

NCT06042608
View directory record Official record
Conditions
Postoperative Pain, Acute, Shoulder Pain
Interventions
intercostobrachial nerve block
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Not applicable Interventional Results available

Transcranial Magnetic Stimulation for Treatment of Insomnia

NCT02196025
View directory record Official record
Conditions
Insomnia
Interventions
Transcranial magnetic stimulation
Device
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 30, 2026, 11:57 PM EDT
Active, not recruiting Phase 2 Interventional

Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium

NCT04060017
View directory record Official record
Conditions
Autism Spectrum Disorder, Language Disorders
Interventions
Levoleucovorin Calcium, Placebo
Drug · Other
Lead sponsor
Southwest Autism Research & Resource Center
Other
Eligibility
30 Months to 60 Months
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 1 Interventional

Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

NCT03780517
View directory record Official record
Conditions
Advanced Nonhaematologic Malignancies
Interventions
BOS172738
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 30, 2026, 11:57 PM EDT
Recruiting Phase 1 Interventional

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

NCT07814248
View directory record Official record
Conditions
NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric Cancer (GC), Endometrial Cancer
Interventions
TS-104
Drug
Lead sponsor
TwoStep Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Maumee, Ohio • Portland, Oregon • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

NCT03538626
View directory record Official record
Conditions
HIV Antibodies
Interventions
VRC-HIVMAB091-00-AB, rHuPH20
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Targeting Oxidative Stress in Chronic Beryllium Disease

NCT01088243
View directory record Official record
Conditions
Chronic Beryllium Disease
Interventions
Mesalamine, Placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Not applicable Interventional

Effects of White Potato Consumption on Measures of Cardiometabolic Health in Individuals With Type 2 Diabetes Mellitus

NCT04511325
View directory record Official record
Conditions
Type2 Diabetes, Cardiometabolic Syndrome, Arterial Stiffness, Overweight and Obesity
Interventions
Potato Regimen, Refined Grain Regimen
Other
Lead sponsor
Florida State University
Other
Eligibility
45 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 30, 2026, 11:57 PM EDT
Recruiting Not applicable Interventional

Effectiveness of Exercise After an ICD

NCT03544489
View directory record Official record
Conditions
Heart Arrest, Implantable Defibrillator User, Physical Activity
Interventions
E-ICD Intervention
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 30, 2026, 11:57 PM EDT
Terminated No phase listed Observational

Evaluation of ARi With OpSens SavvyWire

NCT06295068
View directory record Official record
Conditions
Aortic Valve Insufficiency
Interventions
Transcatheter Aortic Valve Replacement (TAVR), Balloon Aortic Valvuloplasty (BAV)
Device
Lead sponsor
Opsens, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 30, 2026, 11:57 PM EDT
Recruiting Not applicable Interventional

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

NCT04221893
View directory record Official record
Conditions
Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Stage IV Adenocarcinoma of the Gastroesophageal Junction, Stage IVA Esophageal Adenocarcinoma, Stage IVA Esophageal Squamous Cell Carcinoma, Stage IVA Gastric Cancer, Stage IVA Adenocarcinoma of the Gastroesophageal Junction, Stage IVB Esophageal Adenocarcinoma, Stage IVB Esophageal Squamous Cell Carcinoma, Stage IVB Gastric Cancer, Stage IVB Gastroesophageal Junction Adenocarcinoma, Metastatic Anal Canal Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Small Intestinal Carcinoma, Pancreatobiliary Carcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Anal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Radiation Therapy (RT)
Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
San Francisco, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 1 Interventional

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

NCT02124148
View directory record Official record
Conditions
Neoplasm Metastasis, Colorectal Neoplasms, Breast Cancer
Interventions
Prexasertib, Cisplatin, Cetuximab, G-CSF, Pemetrexed, Fluorouracil, LY3023414, Leucovorin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

NCT01134055
View directory record Official record
Conditions
Macular Degeneration
Interventions
pazopanib eye drops, placebo, ranibizumab intravitreal injection
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Oct 30, 2026, 11:57 PM EDT
Recruiting Not applicable Interventional

Neural Mechanisms of Response Inhibition Training for OCRD

NCT05377125
View directory record Official record
Conditions
Obsessive-Compulsive Disorder, Tricholemmoma, Skin-Picking
Interventions
Computerized cognitive training, Computerized placebo training
Behavioral
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
18 Years to 60 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 30, 2026, 11:57 PM EDT
Active, not recruiting Phase 1 Interventional

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

NCT07007117
View directory record Official record
Conditions
Refractory Neuroblastoma, Relapsed Neuroblastoma, High-Risk Neuroblastoma
Interventions
PHOX2B PC-CAR T Cells
Biological
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
1 Year and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 30, 2026, 11:57 PM EDT
Terminated Phase 3 Interventional

INR-Triggered Transfusion In GI Bleeders From ER

NCT01461889
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Gastrointestinal Hemorrhage, Liver Diseases, Transfusion Related Lung Injury
Interventions
Transfuse plasma to High INR target, Transfuse plasma to Low INR target
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High At-Risk Appalachian Patients Oral Cancer Survivors

NCT01504932
View directory record Official record
Conditions
Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Squamous Cell Carcinoma of the Oropharynx, Stage I Verrucous Carcinoma of the Oral Cavity, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage II Verrucous Carcinoma of the Oral Cavity, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
BRB Lozenge, Survey Administration, Laboratory Biomarker Analysis, pharmacological study
Dietary Supplement · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 2 Interventional Results available

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT03739593
View directory record Official record
Conditions
Macular Edema
Interventions
AR-1105-CF1, AR-1105-CF2
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 30, 2026, 11:57 PM EDT
Suspended Phase 1 Interventional

Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma

NCT04309552
View directory record Official record
Conditions
Glioma
Interventions
18F-FMISO PET, 18F-FLT PET
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Not applicable Interventional Results available

Reversing Synchronized Brain Circuits With Targeted Auditory-Somatosensory Stimulation to Treat Phantom Percepts

NCT03621735
View directory record Official record
Conditions
Tinnitus
Interventions
Burst-SCS/sham SCS, Sham SCS/Burst-SCS
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 30, 2026, 11:57 PM EDT
Active, not recruiting No phase listed Observational

Frailty in Patients With Gastrointestinal Cancer Who Are Undergoing Major Surgery

NCT05694338
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Frailty survey
Other
Lead sponsor
The Guthrie Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
East Corning, New York • Sayre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 3 Interventional

Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

NCT04538625
View directory record Official record
Conditions
Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea, Adult Solid Tumor, Prophylaxis of Diarrhea, Symptomatic Relief of Diarrhea, Targeted Therapy-related Diarrhea
Interventions
Crofelemer 125 MG [Mytesi], Placebo
Drug
Lead sponsor
Napo Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
27
States / cities
Prescott, Arizona • Anaheim, California • Corona, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 30, 2026, 11:57 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

MRI in BPD Subjects

NCT03657693
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
NICU MRI, Polysomnography
Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 4 Months
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 30, 2026, 11:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early Screen for Discharge Planning in Community Hospitals

NCT02117804
View directory record Official record
Conditions
Hospitalization
Interventions
Early Screen for Discharge Planning
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Eau Claire, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 30, 2026, 11:57 PM EDT